Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of early-stage investigative therapies in Amgen’s portfolio to treat multiple myeloma and other cancers. A total of 16 early-stage programs are planned to be launched, covering…
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer that starts in the bone marrow. In a recent survey led by researchers at Dana-Farber Cancer Institute and Brigham Women’s Hospital, only 16…
Janssen has decided to discontinue a Phase 1 trial assessing Darzalex (daratumumab) in combination with JNJ-63723283 — an anti-PD-1 antibody — in multiple myeloma patients, Genmab announced. The decision is based on recent findings from the Phase 1b/2 LUC2001 trial (NCT03023423) for non-small cell lung cancer, where a combination…
Researchers in Canada are studying how to reduce the risks associated with the treatment of multiple myeloma by improving the safety and efficacy of stem cell transplants through the use of a new molecule, UM171. Specifically, Jean Roy, MD, a hematologist and professor, and his team at the…
Stand Up to Cancer (SU2C) recently awarded $10 million to a SU2C Dream Team that wants to move the treatment of multiple myeloma from a “watch and wait” approach to early detection of precursor conditions before they turn into fully developed disease. The award was announced at a special…
A Phase 1 clinical trial testing therapy candidate STRO-001 for lymphoma and myeloma has started treating its first patients, announced Sutro Biopharma, the therapy’s maker. The open-label, multicenter trial (NCT03424603) will test the investigational treatment in patients who are intolerant or in whom all other available therapies have failed.
As part of its $15 million Immunotherapy Initiative, the Multiple Myeloma Research Foundation (MMRF) recently awarded $7 million in funding to three innovative research programs designed to accelerate precision immunotherapies for multiple myeloma. The initiative builds collaborative Myeloma Immune Networks of Excellence to reach this goal. “We are thrilled…
AbbVie and the International Myeloma Foundation are collaborating to study the role of a genetic mutation — the t(11;14) translocation — in multiple myeloma treatments and outcomes. The main goal for AbbVie and IMF researchers is to determine the overall survival of 1,500 myeloma patients with a t(11;14) translocation, which…
To raise awareness of multiple myeloma and funding for research, 18 patients, caregivers, and healthcare professionals have embarked on a challenging ascent to Mount Everest Base Camp, from March 3-16. The trek aims to support the Moving Mountains for Multiple Myeloma Program (MM4MM), a joint fundraising effort of the…
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy, also known as CAR-T therapy, for multiple myeloma, Dr. Woodring Wright, a professor of cell biology and cancer researcher, tells the story of his own…
Get regular updates to your inbox.